人类三酸盐异构酶是癌症的潜在目标,这是由于常见的翻译后修改
Sergio Enríquez-Flores1, Ignacio De la Mora-De la Mora1, Itzhel García-Torres1
1Laboratorio de Biomoléculas y Salud Infantil, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico.
Molecules (Basel, Switzerland)
|August 26, 2023
概括
通过翻译后修改而改变的三酸盐异构酶,显示出作为一种新的癌症治疗点的前景. 准这种糖解酶利用癌细胞差异为潜在的治疗策略.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 癌症是一个全球性的健康挑战,发病率和死亡率不断增加,特别是在发展中国家.
- 目前的癌症治疗方法,如化疗和免疫疗法,具有局限性和严重的副作用.
- 癌细胞表现出高的糖解活性,使其与正常细胞区别开来.
研究的目的:
- 探索三酸盐异构酶 (TPI) 作为癌症治疗中的治疗点的潜力.
- 为了研究翻译后修改在癌细胞内TPI的功能中的作用.
主要方法:
- 在癌细胞中分析糖溶性通路酶.
- 检查人类三酸盐异构酶的翻译后修改.
- 在癌症与正常细胞中对TPI进行比较研究.
主要成果:
- 增加的糖解活性是癌细胞的标志.
- 三酸异相酶对于通过糖解产生ATP至关重要.
- 翻译后的修改可以改变三酸异相酶的结构和功能.
结论:
- 三酸异相酶,特别是当转化后修改时,代表了癌症治疗的有希望的标.
- 利用癌症和正常细胞之间糖解酶的差异提供了一个潜在的治疗窗口.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
Covalently Linked Protein Regulators
6.9K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.9K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


